GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Atlantic International Corp (OTCPK:ATLN) » Definitions » Other Operating Expense

ATLN (Atlantic International) Other Operating Expense : $0.48 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Atlantic International Other Operating Expense?

Atlantic International's Other Operating Expense for the three months ended in Sep. 2024 was $1.25 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.48 Mil.

Atlantic International's quarterly Other Operating Expense increased from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($1.25 Mil) but then declined from Jun. 2024 ($1.25 Mil) to Sep. 2024 ($1.25 Mil).

Atlantic International's annual Other Operating Expense increased from Dec. 2021 ($-0.16 Mil) to Dec. 2022 ($-0.08 Mil) and increased from Dec. 2022 ($-0.08 Mil) to Dec. 2023 ($0.00 Mil).


Atlantic International Other Operating Expense Historical Data

The historical data trend for Atlantic International's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atlantic International Other Operating Expense Chart

Atlantic International Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial -0.37 -0.28 -0.16 -0.08 -

Atlantic International Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 -2.02 - 1.25 1.25

Atlantic International Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atlantic International Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Atlantic International's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Atlantic International Business Description

Traded in Other Exchanges
N/A
Address
3 Federal Street, Billerica, MA, USA, 01821
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.
Executives
Daniel Robert Jones officer: President, CEO 317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
Douglas Patrick Miscoll director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
David Pfeffer director 464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos director 317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally officer: CHIEF FINANCIAL OFFICER 66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy officer: CFO, Secretary 166 WINN STREET, WOBURN MA 01801